Canaccord Genuity analyst Mark Massaro downgraded Meridian Biosciences (NASDAQ: VIVO) from Hold to Sell with a price target of $11.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE